The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Must be a buy at .87 !
£30100 @.862 quoted today
Nutraceuticals for Aging and Anti-Aging: Basic Understanding and Clinical Evidence
JN Lokhande, YV Pathak - 2021
https://books.google.co.uk/books?hl=en&lr=&id=IaBMEAAAQBAJ&oi=fnd&pg=PT9&ots=kHhn41vjDx&sig=oKEOhscnjTFtBrIJ80bH5Akn1rE
Since the resident Troll got the whole thread removed again.........
Lu Xiong
Licensed pharmacist (Edited 5 hours ago)
Talking platelets and recommending Fruitflow in answer to a question
Water-soluble tomato concentrate can control platelet aggregation in many ways. On the one hand, it can inhibit protein disulfide isomerase and reduce platelet activation [3]; on the other hand, it can inhibit the activation of integrin aIIbß3 and the expression of CD62P protein on the platelet surface, and reduce platelet aggregation [4]. At the same time, it also has a significant inhibitory effect on platelet aggregation mediated by ADP, collagen, thrombin, and arachidonic acid [4]. In addition, in a number of clinical studies currently conducted, it has found no side effects and can be used for a long time .Therefore, products containing these extracts can also be taken to protect the health of platelets and avoid excessive accumulation of platelets in blood vessels. For example, Xinluoxin, its main ingredient is water-soluble tomato concentrate."
https://www.zhihu.com/question/496136212/answer/2211446186
"What is the mechanism of action of water-soluble tomato concentrate (Fruitflow)?"
2021-11-10
"In recent years, the water-soluble tomato concentrate (Fruitflow) that has attracted much attention in recent years is an effective ingredient for inhibiting platelet aggregation. In the third China Health Food Conference in 2019, a company revealed that it is developing a new water-soluble tomato concentrate. Water-soluble tomato concentrate can effectively reduce the platelet aggregation rate, inhibit the activation of platelet aIIbß3, inhibit FeCl 3 induced mesenteric artery thrombosis, and down-regulate the phosphorylation level of platelet Akt, Erk1/2 and JNK protein without prolonging bleeding time."
https://www.163.com/dy/article/GOEHIGKN0552M4JW.html
ever
who knows who has been doing what. Like many I am surprised that there has never been a holding RNS given all the trades etc....
From my own experience I find the Chinese do not believe anything anyone tells them, they need to check things out themselves - i.e. the EFSA we have means jack to them. They are now obviously very happy with FF now.....
I did pick up on a comment on ADVFN that no one from DSM was at the AGM - might be down to CV19 corporate policy or , as I suspect DSM have lost interest since they no longer have a strangle hold over us.
I do believe IF has been given a push by SL to get on with it now that the patents are in the bag (Brentford etc . sponsorship). probably said don't worry about cash, we'll find you some more if needed, just get on with it. I expect IF has been banging on a number of doors outside China.
As alf has said, this could go vertical any time, and stay up there..
but wtfdik
W$
So Wellsite do you reckon they have been surreptitiously collecting quietly for some time ?
09-Nov-21 10:22:56 0.93 1,070,968 Buy* 9,960
That's higher than they'd sell them for this morning.
Being quoted .855 for £30k - long time since could get a quote for anywhere near that amount !!!!
W£
Why do you car so much about this share Zeus? Guessing you made a big loss here and can't let it go?
Yep, more buys than are showing on here, definitely.
Looks like another decent buy being worked .......
Why so angry?
Why would they move the Ask back to 1.00 straight after a very modest Buy this morning?
Whenever the MM's are deeking about with the sp, they wheel out their snap dogs.
#tooobvious
DP64, The board I was referring to was ADVFN share chat and to be honest I don't post on there very often.
Hi gixer,
I will be interested to read your post on other board. It will be nice to know which board you are referring to.
Spot on gixer, 10K looks a buy to me
I put an email address on the other board that you can contact me on and send your number.
Killed any buying this morning with a spread like that.
Never truer words colt . It’s a sadomasochism beyond belief and utterly depressing .
Long term strategic co-operation framework agreement aside.
This is probably the best publicity Provexis and Fruitflow have had in China.
https://www.baidu.com/s?wd=%22%E6%B1%A4%E8%87%A3%E5%80%8D%E5%81%A5%22%20%22fruitflow%22%20%22%E8%BD%BB%E7%BB%9C%E7%B4%A0%22&pn=0&oq=%22%E6%B1%A4%E8%87%A3%E5%80%8D%E5%81%A5%22%20%22fruitflow%22%20%22%E8%BD%BB%E7%BB%9C%E7%B4%A0%22&ie=utf-8&rsv_pq=a2f20e590007c4d8&rsv_t=482fJxzdEcgY4%2BOKpW4BGUnYH8LGZNISDZyAbE3RvAUuTQBc9SlH98I9AwU&gpc=stf%3D1633515099%2C1636193499%7Cstftype%3D1&tfflag=1&bs=%22%E6%B1%A4%E8%87%A3%E5%80%8D%E5%81%A5%22%20%22fruitflow%22%20%22%E8%BD%BB%E7%BB%9C%E7%B4%A0%22&rsv_jmp=fail
https://www.google.co.uk/search?q=%22%E6%B1%A4%E8%87%A3%E5%80%8D%E5%81%A5%22+%22fruitflow%22&tbas=0&tbs=qdr:w&sxsrf=AOaemvI5xxZiZVCF8WS0cj0QGJSj5KUqmg:1636193421492&ei=jVSGYe24HdXD8gLM1LOQCw&start=0&sa=N&ved=2ahUKEwits6-9v4P0AhXVoVwKHUzqDLI4HhDy0wN6BAgBEDs&biw=1366&bih=625&dpr=1
Guangzhou is smog central in China. An ideal p-lace to launch a product aimed at dealing with the effects of air pollution. I recall thinking "what the hell am I breathing" when I visited it some years ago.
"Focusing on consumer health, the company has continued to try to expand into new business
segments. In 2020, the company has tried to deploy over-the-counter drugs (OTC) business and
functional food business which are still in the incubation period. In the massive health industry
ecosystem centered on VDS, extending upward to OTC, and downward to functional foods, the
company continued to build and enrich the brand matrix in different business segments, and forming a
good complementarity among brand positioning, consumer groups and needs, and constantly
consolidated brand power to create value for consumers' health."
"17. Establishment of Guangzhou Hurui Pharmaceutical Technology Development Co,. Ltd
On August 20, 2020,Guangzhou Hurui Pharmaceutical Investment Co,. Ltdset up a new wholly-owned subsidiary, Guangzhou Hurui Pharmaceutical Technology Development Co,. Ltd, with a registered capital of RMB 10 million and
the executive director of LIN Zhicheng. This company is mainly used for holding OTC approval and outsourced
processing"
https://upload-yyj.by-health.com/upload/files/0324160545898_2020%20Annual%20Report%20(Compact%20Edition).pdf